PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. Its product pipeline also includes other oral NSAIDs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation. The company was founded in 2002 and is headquartered in Houston, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PLXP
Previous Symbol
CUSIPN/A
Phone713-842-1249
Debt
Debt-to-Equity Ratio1.53
Current Ratio4.84
Quick Ratio9.15
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$780,000.00
Price / Sales46.61
Cash FlowN/A
Price / CashN/A
Book Value$0.39 per share
Price / Book10.67
Profitability
EPS (Most Recent Fiscal Year)($1.95)
Net Income$-15,340,000.00
Net Margins-12.09%
Return on Equity-224.24%
Return on Assets-56.12%
Miscellaneous
Employees14
Outstanding Shares8,740,000
Market Cap$36.37 million
OptionableNot Optionable
PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions
What is PLx Pharma's stock symbol?
PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."
How were PLx Pharma's earnings last quarter?
PLx Pharma Inc (NASDAQ:PLXP) announced its quarterly earnings results on Friday, November, 9th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.39). The biotechnology company earned $0.22 million during the quarter. PLx Pharma had a negative return on equity of 224.24% and a negative net margin of 12.09%. View PLx Pharma's Earnings History.
When is PLx Pharma's next earnings date?
What price target have analysts set for PLXP?
1 Wall Street analysts have issued 1-year price objectives for PLx Pharma's shares. Their predictions range from $14.00 to $14.00. On average, they anticipate PLx Pharma's stock price to reach $14.00 in the next year. This suggests a possible upside of 236.5% from the stock's current price. View Analyst Price Targets for PLx Pharma.
What is the consensus analysts' recommendation for PLx Pharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PLx Pharma.
Has PLx Pharma been receiving favorable news coverage?
News coverage about PLXP stock has been trending somewhat positive on Sunday, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. PLx Pharma earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the next several days.
Who are some of PLx Pharma's key competitors?
Some companies that are related to PLx Pharma include VERONA PHARMA P/S (VRNA), DURECT (DRRX), CytoDyn (CYDY), Spero Therapeutics (SPRO), Recro Pharma (REPH), Galmed Pharmaceuticals (GLMD), Melinta Therapeutics (MLNT), Teligent (TLGT), Emisphere Technologies (EMIS), Selecta Biosciences (SELB), Sol Gel Technologies (SLGL), Sesen Bio (SESN), Catalyst Biosciences (CBIO), Sierra Oncology (SRRA) and Northwest Biotherapeutics (NWBO).
Who are PLx Pharma's key executives?
PLx Pharma's management team includes the folowing people:
- Mr. Michael J. Valentino, Exec. Chairman (Age 64)
- Ms. Natasha Giordano, Chief Exec. Officer, Pres and Director (Age 58)
- Mr. Gary L. Mossman, Sr. Advisor (Age 77)
- Mr. Ronald R. Zimmerman, Founder and Sr. Advisor (Age 65)
- Ms. Rita M. O'Connor CPA, Chief Financial Officer (Age 50)
When did PLx Pharma IPO?
(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.
How do I buy shares of PLx Pharma?
Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PLx Pharma's stock price today?
One share of PLXP stock can currently be purchased for approximately $4.16.
How big of a company is PLx Pharma?
PLx Pharma has a market capitalization of $36.37 million and generates $780,000.00 in revenue each year. The biotechnology company earns $-15,340,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. PLx Pharma employs 14 workers across the globe.
What is PLx Pharma's official website?
How can I contact PLx Pharma?
PLx Pharma's mailing address is 8285 EL RIO STREET SUITE 130, HOUSTON TX, 77054. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected]
MarketBeat Community Rating for PLx Pharma (NASDAQ PLXP)
MarketBeat's community ratings are surveys of what our community members think about PLx Pharma and other stocks. Vote "Outperform" if you believe PLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
